Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.

被引：4
|
作者：
Kopetz, Scott
Lonardi, Sara
McDermott, Raymond S.
Aglietta, Massimo
Hendlisz, Alain
Morse, Michael
Leach, Joseph W.
Neyns, Bart
Chan, Emily
Chen, Franklin
Wong, Ka Yeung Mark
Lee, James J.
Garcia-Alfonso, Pilar
Hill, Andrew G.
Lenz, Heinz-Josef
Desai, Jayesh
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3548
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3548
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.
    Andre, Thierry
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Morse, Michael
    McDermott, Raymond S.
    Hill, Andrew Graham
    Hendlisz, Alain
    Lenz, Heinz-Josef
    Leach, Joseph W.
    Moss, Rebecca Anne
    Cao, Z. Alexander
    Ledeine, Jean-Marie
    Chan, Emily
    Kopetz, Scott
    Michael, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
    Lonardi, S.
    Andre, T.
    Wong, K. Y. M.
    Morse, M.
    McDermott, R.
    Hill, A.
    Hendlisz, A.
    Lenz, H.
    Leach, J.
    Moss, R. A.
    Cao, Z. A.
    Ledeine, J.
    Kopetz, S.
    Overman, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
  • [3] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
  • [4] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [5] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
    Andre, T.
    Van Cutsem, E.
    Elez, E.
    Bennouna, J.
    de la Fouchardiere, C.
    Yoshino, T.
    Jensen, L.
    Mendez, G.
    Li, J.
    Goekkurt, E.
    Abdullaev, S.
    Chen, T.
    Lei, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
  • [6] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
    Overman, Michael J.
    Lenz, Heinz-Josef
    Andre, Thierry
    Aglietta, Massimo
    Wong, Mark Ka
    Luppi, Gabriele
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hendlisz, Alain
    Cardin, Dana Backlund
    Morse, Michael
    Neyns, Bart
    Hill, Andrew Graham
    Limon, M. Luisa
    Garcia-Alfonso, Pilar
    Krishnamurthy, Anuradha
    Chen, Franklin
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.
    Overman, Michael J.
    Lonardi, Sara
    Leone, Francesco
    McDermott, Raymond S.
    Morse, Michael A.
    Wong, Ka Yeung Mark
    Neyns, Bart
    Leach, Joseph L.
    Alfonso, Pilar Garcia
    Lee, James J.
    Hill, Andrew
    Lenz, Heinz-Josef
    Desai, Jayesh
    Moss, Rebecca A.
    Cao, Z. Alexander
    Ledeine, Jean-Marie
    Tang, Hao
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [8] A phase III study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW
    Abdullaev, Sandzhar
    Andre, Thierry
    Lei, Ming
    Lenz, Heinz-Josef
    Novotny, James
    Paulson, Andrew Scott
    Tejpar, Sabine
    Yamazaki, Kentaro
    Ledeine, Jean-Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [9] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [10] First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.
    Andre, Thierry
    Elez, Elena
    Lenz, Heinz-Josef
    Jensen, Lars Henrik
    Touchefeu, Yann
    Van Cutsem, Eric
    Garcia-Carbonero, Rocio
    Tougeron, David
    Mendez, Guillermo
    Schenker, Michael
    de la Fouchardiere, Christelle
    Limon, Maria Luisa
    Yoshino, Takayuki
    Li, Jin
    Aubin, Francine
    Cela, Elvis
    Chen, Tian
    Lei, Ming
    Jin, Lixian
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : LBA143 - LBA143
12345